Navigation Links
Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
Date:1/31/2012

DURHAM, N.C., Jan. 31, 2012 /PRNewswire/ -- Argos Therapeutics Inc., today announced that it presented a high resolution immune monitoring analysis of AGS-003-006, a Phase 2 study of its Arcelis™ immunotherapy, AGS-003, in combination with sunitinib in patients with advanced renal cell carcinoma (RCC). The results showed a statistically significant correlation between anti-tumor memory T cell responses and overall survival. AGS-003 in combination with sunitinib overcame the immuno-suppressive environment of RCC and induced a tumor-specific multi-functional memory CTL response. The results were presented orally at the Global Technology Community's (GTC) 4th Immunotherapeutics and Immunomonitoring Conference in San Diego.

"We believe that the high resolution immune monitoring analysis of the Phase 2 study of AGS-003 and sunitinib represents the first time that pattern recognition algorithms originally developed for gene microarray datasets have been applied to an immunologic dataset to identify immune correlates to clinical outcome," said Charles Nicolette, Ph.D., Argos' chief scientific officer and vice president of research and development. "The multiparametric flow cytometry data from the study that we analyzed demonstrated that the combination of AGS-003 and sunitinib induced tumor-specific multi-functional memory CTL that were statistically significant correlates to overall survival in the study, thereby supporting the intended mechanism of action of AGS-003."

AGS-003-006 was an open label Phase 2 trial of AGS-003 in combination with sunitinib in patients with newly diagnosed, unfavorable-risk, metastatic clear cell RCC. AGS-003 was designed to stimulate the proliferation and multi-functionality of CTLs targeted directly to the autologous RCC tumor antigens.  In analyzing the data from the trial we sought to detect immune correlates by using multi-parametric flow cytometry to identify 16 unique RCC antigen reactive CTL subsets based on the expression of the surface markers CD28, CD45RA, CD27 and CCR7, present in blood draws collected prior to treatment with AGS-003 or sunitinib and after administration of five doses of AGS-003 in combination with sunitinib.  Furthermore, each CTL subset was partitioned to an additional 64 functional subsets based on the expression of three cytokines (IFN-g, TNF-a, IL-2), lytic function (Granyme b, CD107 expression) and proliferation.  Correlates of CTL subsets with subjects' clinical lab characteristics were analyzed using an adaption of a binary tree-structured vector quantization (BTSVQ) approach used to cluster and visualize microarray data. The BTSVQ approach implements a two-way unsupervised clustering that allows each subject's clinical lab assessments, progression-free survival (PFS) and overall survival (OS) to be mapped back to immune responses to identify unique clustering patterns with clinical value. The data analysis identified one subset of CTL, with the CD8+CD28+CD45RA- memory CTL phenotype that trended with longer disease free intervals and was a statistically significant correlate to overall survival.

About the Arcelis™ Technology

Arcelis is Argos´ proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies. This platform is based on optimizing a patient´s own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient´s disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient´s disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is fully personalized for each patient's disease.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.  

Contact:
Jeff Abbey
Argos Therapeutics
(919) 287-6308
jabbey@argostherapeutics.com


'/>"/>
SOURCE Argos Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
2. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
3. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
5. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
7. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Silence Therapeutics Additional Listing
10. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
11. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics ... biotherapeutics development, announces the launch of the new NHS Agile biosensor chip ... binding data for a wide range of molecules, including small and large molecules, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, a ... downlights designed to stay tightly sealed and perform efficiently for years. The downlights ... location listings just aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; containment ...
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO USA introduces its new ... website makes it easy to navigate through the site whether you’re in the ... product information, educational industry content and visit the company’s social media accounts, all ...
(Date:8/14/2017)... New York, NY (PRWEB) , ... August 14, 2017 , ... ... Mobile in Clinical Trials event, which will take place on September 6, 2017 ... Daniel Karlin, MD , Head of Experimental Medicine, Informatics, and Regulatory Strategy, Pfizer ...
Breaking Biology Technology:
(Date:6/14/2017)... -- IBM (NYSE: IBM ) is introducing several innovative partner ... developing collaboration between startups and global businesses, taking place in ... event, nine startups will showcase the solutions they have built ... France is one of ... 30 percent increase in the number of startups created between ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
Breaking Biology News(10 mins):